))
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Manage episode 414856476 series 3381434
Contenido proporcionado por ReachMD. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente ReachMD o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-therapeutic-selection-for-a-patient-with-newly-diagnosed-braf-v600e-mutated-metastatic-melanoma/24365/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
…
continue reading
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-therapeutic-selection-for-a-patient-with-newly-diagnosed-braf-v600e-mutated-metastatic-melanoma/24365/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
680 episodios
Compartir
